

# UPADACITINIB

2020

CELEST

Phase 2/ UPA different doses vs placebo/ CD / Induction

Conclusion:

**UPA induced endoscopic remission in a significant proportion of patients compared with placebo.**

2020

U-ACHIEVE

Phase 2b/ UPA/ UC/ Induction

Conclusion

**8 weeks of treatment with UPA was more effective than placebo for inducing remission in patients with moderately to severely active UC.**

2022

U-ACHIEVE  
U-ACCOMPLISH

Phase 3/ UPA/ UC/ Induction & Maintenance

Conclusion:

**Upadacitinib is more effective than placebo for both induction and maintenance of remission in ulcerative colitis**

2023

U-EXCEL  
U-EXCEED  
U-ENDURE

Phase 3/UPA/ CD/Induction & Maintenance

Conclusion

**Upadacitinib induction and maintenance treatment was superior to placebo in patients with moderate-to-severe Crohn's disease.**